Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand

International Journal of Pharmaceutics

Volumn 363, Issue 1-2, 2008, Pages 149-154

  Na, Seong Ju ^a   Chae, Su Young ^b   Lee, Seulki ^c   Park, Kyeongsoon ^c   Kim, Kwangmeyung ^c   Park, Jae Hyung ^a   Kwon, Ick Chan ^c   Jeong, Seo Young ^a   Lee, Kang Choon ^b  

^a Kyung Hee University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

Hyaluronic acid; Nanocomplex; Protein stability; TRAIL

Indexed keywords

HYALURONIC ACID; NANOCOMPLEX; NANOPARTICLE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; HELA CELLS; HUMANS; HYALURONIC ACID; INJECTIONS, SUBCUTANEOUS; MALE; NANOPARTICLES; PROTEIN STABILITY; RATS; RATS, SPRAGUE-DAWLEY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 51649117750     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.07.013     Document Type: Article

References (33)

1. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
2. Bartus R.T., Tracy M.A., Emerich D.F., and Zale S.E. Sustained delivery of proteins for novel therapeutic agents. Science 281 (1998) 1161-1162
3. Bremer E., van Dam G., Kroesen B.J., de Leij L., and Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol. Med. 12 (2006) 382-393
4. Cretney E., Takeda K., and Smyth M.J. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int. J. Biochem. Cell Biol. 39 (2007) 280-286
5. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug. Discov. 2 (2003) 347-360
6. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
7. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5 (2005) 876-885
8. Fraser J.R., Laurent T.C., and Laurent U.B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242 (1997) 27-33
9. Fu K., Pack D.W., Klibanov A.M., and Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17 (2000) 100-106
10. Ganson N.J., Kelly S.J., Scarlett E., Sundy J.S., and Hershfield M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 8 (2006) R12
11. Hahn S.K., Kim S.J., Kim M.J., and Kim D.H. Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. Pharm. Res. 21 (2004) 1374-1381
12. Ishida T., Atobe K., Wang X., and Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Rel. 115 (2006) 251-258
13. Johnson O.L., Cleland J.L., Lee H.J., Charnis M., Duenas E., Jaworowicz W., Shepard D., Shahzamani A., Jones A.J., and Putney S.D. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 2 (1996) 795-799
14. Judge A., McClintock K., Phelps J.R., and Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13 (2006) 328-337
15. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., and Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp Ther. 299 (2001) 31-38
16. Kelly S.J., Delnomdedieu M., Oliverio M.I., Williams L.D., Saifer M.G., Sherman M.R., Coffman T.M., Johnson G.A., and Hershfield M.S. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J. Am. Soc. Nephrol. 12 (2001) 1001-1009
17. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., and Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
18. Lee B.K., Kwon J.S., Kim H.J., Yamamoto S., and Lee E.K. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug. Chem. 18 (2007) 1728-1734
19. Lee E.S., Park K.H., Kang D., Park I.S., Min H.Y., Lee D.H., Kim S., Kim J.H., and Na K. Protein complexed with chondroitin sulfate in poly(lactide-co-glycolide) microspheres. Biomaterials 28 (2007) 2754-2762
20. Liao Y.H., Jones S.A., Forbes B., Martin G.P., and Brown M.B. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 12 (2005) 327-342
21. Park J.H., Ye M., Yeo Y., Lee W.K., Paul C., and Park K. Reservoir-type microcapsules prepared by the solvent exchange method: effect of formulation parameters on microencapsulation of lysozyme. Mol. Pharm. 3 (2006) 135-143
22. Putney S.D., and Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16 (1998) 153-157
23. Ray S., and Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63 (2003) 4713-4723
24. Schaefer U., Voloshanenko O., Willen D., and Walczak H. TRAIL: a multifunctional cytokine. Front. Biosci. 12 (2007) 3813-3824
25. Tamber H., Johansen P., Merkle H.P., and Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 57 (2005) 357-376
26. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
27. Wagner V., Dullaart A., Bock A.K., and Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24 (2006) 1211-1217
28. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
29. Wei G., Pettway G.J., McCauley L.K., and Ma P.X. The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres. Biomaterials 25 (2004) 345-352
30. Xiang H., Nguyen C.B., Kelley S.K., Dybdal N., and Escandon E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab. Dispos. 32 (2004) 1230-1238
31. Yeo Y., and Park K. A new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchange. J. Control. Rel. 100 (2004) 379-388
32. Youn Y.S., Shin M.J., Chae S.Y., Jin C.H., Kim T.H., and Lee K.C. Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biotechnol. Lett. 29 (2007) 713-721
33. Zhu G., Mallery S.R., and Schwendeman S.P. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat. Biotechnol. 18 (2000) 52-57